{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T10:22:01Z","timestamp":1780827721207,"version":"3.54.1"},"reference-count":128,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartfailure.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.hfc.2017.02.004","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T12:15:17Z","timestamp":1497010517000},"page":"467-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults"],"prefix":"10.1016","volume":"13","author":[{"given":"Wilbert S.","family":"Aronow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2017.02.004_bib1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCULATIONAHA.105.167587","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib3","doi-asserted-by":"crossref","first-page":"M483","DOI":"10.1093\/gerona\/57.8.M483","article-title":"What is the appropriate treatment of hypertension in elders?","volume":"57A","author":"Aronow","year":"2002","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib4","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib5","doi-asserted-by":"crossref","first-page":"M138","DOI":"10.1093\/gerona\/56.3.M138","article-title":"Treatment of older persons with hypercholesterolemia with and without cardiovascular disease","volume":"56A","author":"Aronow","year":"2001","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9149(02)02438-4","article-title":"Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol \u2265125 mg\/dL treated with statins versus no lipid-lowering drug","volume":"90","author":"Aronow","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib7","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib8","doi-asserted-by":"crossref","first-page":"M573","DOI":"10.1093\/gerona\/58.6.M573","volume":"58A","author":"Aronow","year":"2003","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib9","doi-asserted-by":"crossref","first-page":"M1046","DOI":"10.1093\/gerona\/58.11.M1046","volume":"58A","author":"Sanal","year":"2003","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib10","doi-asserted-by":"crossref","first-page":"M432","DOI":"10.1093\/gerona\/58.5.M432","volume":"58A","author":"Ghosh","year":"2003","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib11","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2015.02.038","article-title":"AHA\/ACC\/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"65","author":"Rosendorff","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib12","first-page":"3","article-title":"Management of atrial fibrillation in the elderly","volume":"100","author":"Aronow","year":"2009","journal-title":"Minerva Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1076-7460.2001.00803.x","article-title":"Exercise therapy for older persons with cardiovascular disease","volume":"10","author":"Aronow","year":"2001","journal-title":"Am J Geriatr Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib18","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJM199511023331806","article-title":"A\u00a0multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure","volume":"333","author":"Rich","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib19","first-page":"1488","volume":"68","author":"Yancy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mhj.2002.123144","article-title":"Diuretic resistance predicts mortality in patients with advanced heart failure","volume":"144","author":"Neuberg","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2017.02.004_bib21","first-page":"1429","article-title":"Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib24","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib25","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"Kober","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib29","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0002-9149(01)02092-6","volume":"88","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib30","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0735-1097(02)01943-5","article-title":"Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients","volume":"40","author":"Dries","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib34","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1111\/j.1365-2125.1989.tb03585.x","article-title":"Why are converting enzyme inhibitors vasodilators?","volume":"28","author":"Vanhoutte","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hfc.2017.02.004_bib35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM198304073081402","article-title":"Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients","volume":"308","author":"Weksler","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/0735-1097(92)90449-W","article-title":"Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure","volume":"20","author":"Hall","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2125.1996.00480.x","article-title":"Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid","volume":"42","author":"Boger","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hfc.2017.02.004_bib38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0735-1097(95)00006-P","article-title":"Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure","volume":"25","author":"Evans","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0735-1097(99)00180-1","article-title":"Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril","volume":"34","author":"Katz","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9149(96)00696-0","article-title":"Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"79","author":"Nguyen","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(97)00502-0","article-title":"Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib42","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/S0735-1097(99)00129-1","article-title":"Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease","volume":"33","author":"Leor","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib43","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1046\/j.1532-5415.2002.50305.x","article-title":"Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure?","volume":"50","author":"Lapane","year":"2002","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.hfc.2017.02.004_bib45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinte.1993.00410080011002","article-title":"Tissue renin-angiotensin system in myocardial hypertrophy and failure","volume":"153","author":"Dzau","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib46","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0024-3205(97)00146-X","article-title":"Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men","volume":"60","author":"Jilma","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib48","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib49","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib50","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib51","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib52","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib54","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A\u00a0randomized trial of propranolol in patients with acute myocardial infarction","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib55","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM198510243131705","article-title":"Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction","volume":"313","author":"Pedersen","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.CIR.73.3.503","article-title":"Effect of propranolol after acute myocardial infarction in patients with congestive heart failure","volume":"73","author":"Chadda","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-9149(94)90308-5","article-title":"Beta blocker therapy in the Cardiac Arrhythmia Suppression Trial","volume":"74","author":"Kennedy","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0002-9149(94)90369-7","article-title":"Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients R62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction R40%","volume":"74","author":"Aronow","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0002-9149(00)01504-6","article-title":"Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus","volume":"87","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib60","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0002-9149(01)01521-1","article-title":"Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease","volume":"87","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/01.CIR.69.4.761","article-title":"Effect of propranolol in postinfarction patients with mechanical or electrical complications","volume":"69","author":"Furberg","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib62","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib64","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib65","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2017.02.004_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.med.53.082901.104004","article-title":"New therapeutics for chronic heart failure","volume":"53","author":"Mann","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib68","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0735-1097(00)01121-9","article-title":"Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy","volume":"37","author":"Ohtsuka","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib69","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/hs0202.102332","article-title":"Effect of controlled release\/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study","volume":"33","author":"Wiklund","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.hfc.2017.02.004_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study","volume":"29","author":"Moye","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib71","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib72","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/euhj.2001.2783","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure","volume":"22","author":"Task Force for the Diagnosis and Treatment of Chronic Heart Failure","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2017.02.004_bib73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib74","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib76","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib78","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0735-1097(01)01442-5","article-title":"Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG Study","volume":"38","author":"Rich","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib79","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib80","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hfc.2017.02.004_bib81","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejheart.2005.10.002","article-title":"Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction","volume":"8","author":"Ahmed","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2017.02.004_bib82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2165\/00002512-199101020-00002","article-title":"Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?","volume":"1","author":"Aronow","year":"1991","journal-title":"Drugs Aging"},{"key":"10.1016\/j.hfc.2017.02.004_bib83","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib84","first-page":"612","article-title":"Effects of enrasentan, a nonselective endothelin receptor antagonist in class II to III heart failure: results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation","volume":"38","author":"Abraham","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib85","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/01.CIR.0000014771.38666.22","article-title":"New therapeutic options in congestive heart failure: part II","volume":"105","author":"McMurray","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib86","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib87","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1001\/jama.291.16.2017","article-title":"Vasopressin receptor antagonists. Will the \u201cvaptans\u201d fulfill their promise?","volume":"291","author":"Francis","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib88","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib89","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/MJT.0000000000000473","article-title":"Limitations of sacubitril\/valsartan in the management of heart failure","volume":"24","author":"Yandrapalli","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.hfc.2017.02.004_bib90","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.82.6.1954","article-title":"A\u00a0prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure","volume":"82","author":"Elkayam","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib91","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction","volume":"319","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib93","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib94","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.96.3.856","article-title":"Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Vasodilator-Heart Failure\u00a0Trial (V-HeFT) Study Group","volume":"96","author":"Cohn","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib95","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib96","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib97","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib98","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2017.02.004_bib99","first-page":"24","article-title":"CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction","volume":"60","author":"Aronow","year":"2005","journal-title":"Geriatrics"},{"key":"10.1016\/j.hfc.2017.02.004_bib100","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib101","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":"Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The MIRACLE ICD trial","volume":"289","author":"Young","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib102","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib103","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac- resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib104","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib105","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib106","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/eurheartj\/ehr162","article-title":"Cardiac resynchronization in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial","volume":"32","author":"Brignole","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2017.02.004_bib107","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.amjcard.2009.01.023","article-title":"Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices","volume":"103","author":"Vatankulu","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib108","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure","volume":"325","author":"Packer","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl I","key":"10.1016\/j.hfc.2017.02.004_bib109","first-page":"I-301","article-title":"Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]","volume":"88","author":"Packer","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.82.3.774","article-title":"Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure","volume":"82","author":"Uretsky","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib111","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","article-title":"A\u00a0dose-dependent increase in mortality with vesnarinone among patients with severe heart failure","volume":"339","author":"Cohn","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib112","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/hrt.76.3.223","article-title":"Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) Trial","volume":"76","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2017.02.004_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(90)91517-E","article-title":"Xamoterol in severe heart failure","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib114","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(96)10488-8","article-title":"Randomized study of effect of ibopamine on survival in patients with advanced heart failure","volume":"349","author":"Hampton","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2017.02.004_bib115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","article-title":"Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)","volume":"138","author":"O\u2019Connor","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2017.02.004_bib116","doi-asserted-by":"crossref","first-page":"29060","DOI":"10.3390\/ijms161226147","article-title":"Use of inotropic agents in treatment of systolic heart failure","volume":"16","author":"Tariq","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hfc.2017.02.004_bib117","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib118","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1161\/01.CIR.0000160874.48045.54","article-title":"Nesiritide and worsening of renal function. The emperor\u2019s new clothes?","volume":"111","author":"Teerlink","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib119","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2017.02.004_bib120","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2017.02.004_bib121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib122","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0735-1097(01)01119-6","article-title":"Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction","volume":"37","author":"Athanasuleas","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2017.02.004_bib123","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa0900559","article-title":"Coronary bypass surgery with or without surgical ventricular reconstruction","volume":"360","author":"Jones","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib124","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib125","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa1100358","article-title":"Myocardial viability and survival in ischemic left ventricular dysfunction","volume":"364","author":"Bonow","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib126","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. dysfunction","volume":"374","author":"Velazquez","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib127","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Longterm use of a left ventricular assist device for endstage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2017.02.004_bib128","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"Slaughter","year":"2009","journal-title":"N\u00a0Engl J Med"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171361730017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171361730017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T21:22:59Z","timestamp":1535750579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171361730017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":128,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S155171361730017X"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2017.02.004","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2017.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}